MOTCO’s Indivior Pharmaceuticals INDV Stock Holding History

MOTCO’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-89	Closed	-$2.05K	–	782
2023 Q3	$2.05K	Buy	+89	New	+$2.03K	﹤0.01%	635

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MOTCO's INDV Position: Q4 2023 in Review

MOTCO sold out of Indivior Pharmaceuticals (INDV) in Q4 2023, closing a stake of 89 shares — an estimated $2.05K sold.

MOTCO first reported a position in INDV in Q3 2023 and held it in 1 quarter. The position peaked at $2.05K in Q3 2023. 76 funds tracked by Wall St. Rank hold INDV as of Q4 2023.

MOTCO reported no remaining Indivior Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
MOTCO sold 89 Indivior Pharmaceuticals shares in Q4 2023, an estimated $2.05K.
MOTCO first reported a position in Indivior Pharmaceuticals in Q3 2023 and held it in 1 quarter.
MOTCO's Indivior Pharmaceuticals position peaked at $2.05K in Q3 2023.
76 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2023.

Based on MOTCO's 13F filing for Q4 2023, filed 9 Feb 2024.